Infinium Global Research Diabetes Drug Therapy Market | Page 2

A latest report has been added to the wide database of Diabetes Drug Therapy Market by Infinium Global Research. This
report studies the Diabetes Drug Therapy Market by type (includes insulin, biguanides, meglitinides, sulfonylureas, inhibitors,
and, others) market status and outlook of global and major regions, from manufacturers, and end industries. The objective of
the study is to identify market sizes of different segments & countries in recent years and to forecast the values for the next
six years. Diabetes Drug Therapy Market provides opportunities in micro markets for stakeholders to invest along with the
detailed analysis of competitive landscape, latest trends, and product offerings of the major companies in the Diabetes Drug
Therapy Market. According to the report the Asia-Pacific Diabetes Drug Therapy Market is projected to grow at a CAGR
between 10.0% and 10.5% in terms of value over the period of 2017-2023. The growth in the world market is primarily driven
by significant contribution by North America (Leading region) region to this market.
Market Insights:
The report identified that Asia-Pacific diabetes drug therapy is driven by factors such as growing number of diabetes
population, large number of drugs under pipeline, and, need for new treatments with improved efficacy and launch of new
generation of products for the treatment. While the restraining factors include cost restrains in the developing regions, and,
Lack of awareness, and, less variability in products. Further, the report identifies the opportunities in the world market as rise
in healthcare expenditure in the developing countries, such as India and China. Diabetes is group of metabolic disorder, often
referred as diabetes mellitus, results in high blood glucose levels. Body cells use glucose as a source of energy and insulin is
important for the cells to absorb this glucose. When the body cells loose the capacity to respond to the insulin or body is not
capable of producing sufficient insulin, it leads to an increase in blood glucose levels in the body. This condition is referred to
as diabetes. Depending on the cause of development, it is divided into three types, which includes type 1 diabetes (body
loses the capacity of producing sufficient insulin), type 2 diabetes (most common and body cells do not respond to insulin)
and gestational diabetes (occurs in pregnant women). Among these, type 2diabetes is the most common type and affects
over 90% of the global diabetic patients.
Segments Covered
The report on Asia-Pacific diabetes drug therapy market covers type segments. The type segment includes insulin,
biguanides, meglitinides, sulfonylureas, inhibitors, and, others.
Geographic Coverage and Analysis:
The report provides analysis covering countries such as China, Japan, India, and Rest of the APAC. In this section the key
trends and market size for each country is provided over the period of 2015 – 2023.